0001104659-19-071119.txt : 20191209 0001104659-19-071119.hdr.sgml : 20191209 20191209210032 ACCESSION NUMBER: 0001104659-19-071119 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191205 FILED AS OF DATE: 20191209 DATE AS OF CHANGE: 20191209 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: McBarron Paul CENTRAL INDEX KEY: 0001357397 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-50626 FILM NUMBER: 191276396 MAIL ADDRESS: STREET 1: C/O CYCLACEL PHARMACEUTICALS, INC. STREET 2: 200 CONNELL DRIVE, SUITE 1500 CITY: BERKELEY HEIGHTS STATE: NJ ZIP: 07922 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cyclacel Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001130166 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 911766850 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 CONNELL DRIVE STREET 2: SUITE 1500 CITY: BERKELEY HEIGHTS STATE: NJ ZIP: 07922 BUSINESS PHONE: 908-517-7330 MAIL ADDRESS: STREET 1: 200 CONNELL DRIVE STREET 2: SUITE 1500 CITY: BERKELEY HEIGHTS STATE: NJ ZIP: 07922 FORMER COMPANY: FORMER CONFORMED NAME: XCYTE THERAPIES INC DATE OF NAME CHANGE: 20001218 4 1 tm1924755d1_4.xml OWNERSHIP DOCUMENT X0306 4 2019-12-05 0 0001130166 Cyclacel Pharmaceuticals, Inc. CYCC 0001357397 McBarron Paul 200 CONNELL DRIVE, SUITE 1500 BERKELEY HEIGHTS NJ 07922 1 1 0 0 E. VP, Fin, CFO and COO Option 1.74 2019-12-05 4 A 0 13022 0 A 2027-12-29 Common Stock 13022 13022 D Option 1.56 2019-12-05 4 A 0 11980 0 A 2028-02-22 Common Stock 11980 11980 D On December 29, 2017, Paul McBarron was granted an option to purchase certain shares of common stock, which option shall vest according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on December 5, 2019, resulting in the vesting of the option as to 13,022 shares. On February 22, 2018, Paul McBarron was granted an option to purchase certain shares of common stock, which option shall vest according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on December 5, 2019, resulting in the vesting of the option as to 11,980 shares. /s/ Paul McBarron 2019-12-09